Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03062267 · ClinicalTrials.gov registry record · NA
Effectiveness of a Mobile Texting Intervention for People With Serious Mental Illness
A NA study of Schizophrenia and Major Depressive Disorder, sponsored by University of Washington.
- Completed
- Registry status
- NA
- Development phase
- 49
- Enrollment target
- 2
- Study locations
NCT03062267: Completed NA study of Schizophrenia and Major Depressive Disorder, sponsored by University of Washington.
NCT03062267 is a NA study of Schizophrenia and Major Depressive Disorder that has completed, run by University of Washington. The registered enrollment target is 49 participants, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (78% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03062267, a NA study of Schizophrenia and Major Depressive Disorder, has completed, sponsored by University of Washington.
- COMPLETED
- Registry status
- NA
- Development phase
- 49 participants
- Enrollment target
- 2
- Study locations
Study Summary
Testing an mHealth mobile interventionist texting program on illness management.
Primary Outcome
Assessed with the Psychotic Symptom Rating Scales (PSYRATS). The PSYRATS inquires about the specific dimensions of hallucinations and delusions. There are 17 items and each item is rated from 0 (absent) to 4 (severe). The PSYRATS has 2 subscales: the auditory hallucinations subscale (AHS) consisting of 11 items, and the delusions subscale (DS) consisting of 6 items. These subscale scores are added to create a total score ranging from 0-68. Higher scores indicate worse symptoms.
Conditions Studied
Interventions
- OTHER Mobile Interventionist
Study Locations (2)
Illinois
- Thresholds - Chicago
Washington
- Frontier Behavioral Health - Spokane
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2017-10-01 |
| Est. Completion | 2020-05-31 |
| Phase | NA |
What the finished NCT03062267 record still lists
NCT03062267 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 49 participants, a relatively small participant target, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (78% lower).
The record links to 4 conditions, with Schizophrenia appearing as the primary indexed condition, and to 1 intervention - of which Mobile Interventionist is the first listed.
NCT03062267 reports a single indexed study location in Illinois, Washington.
Frequently Asked Questions
What is clinical trial NCT03062267 about?
NCT03062267 is a clinical study titled "Effectiveness of a Mobile Texting Intervention for People With Serious Mental Illness". Testing an mHealth mobile interventionist texting program on illness management.
What is the current status of trial NCT03062267?
This trial is currently completed. It is a NA study. The enrollment target is 49 participants. The study started on 2017-10-01. Estimated completion is 2020-05-31.
What conditions does trial NCT03062267 study?
This clinical trial studies the following conditions: Schizophrenia, Major Depressive Disorder, Bipolar Disorder, Schizoaffective Disorder.
What interventions are being tested in trial NCT03062267?
The interventions under investigation include: Mobile Interventionist (OTHER).
Who is sponsoring clinical trial NCT03062267?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03062267 being conducted?
This trial has 2 study locations across Illinois, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Schizophrenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03062267's enrollment target sits among peer trials
49 216th of 315 higher than 99 of 315 other Schizophrenia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Schizophrenia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Taking Action for College Students
RECRUITING · NA
-
Enhancing Prefrontal Oscillations and Working Memory in Early-course Schizophrenia
RECRUITING · NA
-
Getting Out of the House: Using Behavioral Activation to Increase Community Participation
RECRUITING · NA
-
Enhancing Brain Connectivity in Schizophrenia Through Neuromodulation (Study 1)
RECRUITING · NA
-
Cerebellar Modulation of Cognition in Psychosis
RECRUITING · NA
-
TMS for Inhibition Enhancement in Schizophrenia
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02704858 · 49 participants · Phase 1
Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma
- NCT03516708 · 49 participants · Phase 1
Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer
- NCT03692429 · 49 participants · Phase 1
alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells
- NCT04329494 · 49 participants · Phase 1
PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI